ARK Investment Management LLC Increases Stake in 10x Genomics $TXG

Key Points

• ARK Investment Management LLC increased its stake in 10x Genomics (NASDAQ:TXG) by 8.1%, totaling approximately 13.89 million shares, making it the firm's 23rd largest holding.
• 10x Genomics reported a quarterly earnings per share of $0.28, significantly exceeding analysts' estimates of ($0.35) per share, while its revenue increased by 12.9% year-over-year.
• Several institutional investors, including GAMMA Investing LLC and Summit Trail Advisors LLC, have made substantial increases to their positions in 10x Genomics, contributing to the total ownership of institutional investors at 84.68%.

ARK Investment Management LLC increased its position in shares of 10x Genomics (NASDAQ:TXG - Free Report) by 8.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 13,892,103 shares of the company's stock after buying an additional 1,046,390 shares during the period. 10x Genomics comprises approximately 1.2% of ARK Investment Management LLC's holdings, making the stock its 23rd largest holding. ARK Investment Management LLC owned about 11.28% of 10x Genomics worth $160,871,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in TXG. GAMMA Investing LLC increased its stake in shares of 10x Genomics by 81.8% during the first quarter. GAMMA Investing LLC now owns 3,586 shares of the company's stock valued at $31,000 after buying an additional 1,614 shares during the period. Wealth Enhancement Advisory Services LLC increased its stake in shares of 10x Genomics by 9.0% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 31,061 shares of the company's stock valued at $271,000 after buying an additional 2,564 shares during the period. Diversified Trust Co increased its stake in shares of 10x Genomics by 60.8% during the first quarter. Diversified Trust Co now owns 57,236 shares of the company's stock valued at $500,000 after buying an additional 21,634 shares during the period. Summit Trail Advisors LLC increased its stake in shares of 10x Genomics by 251.1% during the first quarter. Summit Trail Advisors LLC now owns 36,039 shares of the company's stock valued at $315,000 after buying an additional 25,775 shares during the period. Finally, Teacher Retirement System of Texas purchased a new position in shares of 10x Genomics during the first quarter valued at $123,000. Hedge funds and other institutional investors own 84.68% of the company's stock.

10x Genomics Stock Performance

Shares of TXG stock opened at $13.03 on Wednesday. 10x Genomics has a fifty-two week low of $6.78 and a fifty-two week high of $18.21. The firm has a market capitalization of $1.62 billion, a price-to-earnings ratio of -18.61 and a beta of 2.05. The stock's 50-day simple moving average is $12.89 and its 200-day simple moving average is $11.24.

10x Genomics (NASDAQ:TXG - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.28 earnings per share for the quarter, topping analysts' consensus estimates of ($0.35) by $0.63. 10x Genomics had a negative return on equity of 12.88% and a negative net margin of 13.13%.The business had revenue of $172.91 million for the quarter, compared to analyst estimates of $139.36 million. During the same quarter in the previous year, the firm earned ($0.32) earnings per share. The company's revenue was up 12.9% on a year-over-year basis. 10x Genomics has set its Q3 2025 guidance at EPS. As a group, equities analysts forecast that 10x Genomics will post -1.43 earnings per share for the current year.

Insider Transactions at 10x Genomics

In other news, insider Benjamin J. Hindson sold 7,486 shares of the business's stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $13.79, for a total transaction of $103,231.94. Following the sale, the insider owned 440,888 shares in the company, valued at approximately $6,079,845.52. The trade was a 1.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Adam Taich sold 22,315 shares of the business's stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $307,723.85. Following the sale, the chief financial officer owned 309,273 shares in the company, valued at $4,264,874.67. The trade was a 6.73% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 39,149 shares of company stock worth $539,865. Insiders own 10.03% of the company's stock.

Analyst Upgrades and Downgrades

TXG has been the topic of several research reports. Canaccord Genuity Group set a $16.00 price target on 10x Genomics in a research note on Monday, August 11th. Deutsche Bank Aktiengesellschaft set a $14.00 target price on 10x Genomics and gave the company a "hold" rating in a research note on Friday, August 8th. Piper Sandler started coverage on 10x Genomics in a research note on Thursday, September 11th. They issued a "neutral" rating and a $15.00 target price on the stock. Morgan Stanley cut their target price on 10x Genomics from $18.00 to $17.00 and set an "overweight" rating on the stock in a research note on Tuesday, August 12th. Finally, Wall Street Zen upgraded 10x Genomics from a "hold" rating to a "buy" rating in a research note on Friday, October 3rd. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $13.65.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.

Want to see what other hedge funds are holding TXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 10x Genomics (NASDAQ:TXG - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.